logo

Search

Login | Create Account

oncology


Categories

Blood Breast cancer Cancer care Childhood cancers End-of-life care Endocrine GI cancer GU cancer Head and neck cancer Lung cancer Medicines Medicopolitical Melanoma Podcasts Radiation oncology Research Risk Factors Sarcoma

Other

Conferences

Specialties


Cardiology Dermatology Endocrinology Gastroenterology Haematology Neurology Oncology Respiratory Rheumatology

General


Contact Us About Us Website Disclaimer Privacy Policy Terms & Conditions

©2022 the limbic

logo

ESMO Virtual 2020

Friday 18th - Tuesday 22nd September 2020

Medicines

Drugging the undruggable? KRAS inhibitor shows early promise

Selective inhibition of the KRAS p.G12C mutation is offering some promise for patients with locally advanced and metastatic solid tumours. A phase 1 trial of sotorasib in 129 patients - including Australians - with mainly non-small cell lung cancer (NSCLC) and...

Selective inhibition of the KRAS p.G12C mutation is offering some promise for patients with locally advanced and metastatic solid tumours. A...


Breast cancer

New first-in-class treatment option for triple negative breast cancer

Sacituzumab govitecan should become the new standard of care in women with previously treated metastatic triple-negative breast cancer (mTNBC), according to discussion at ESMO 2020. A phase 3 study, presented at the ESMO Virtual Congress 2020, randomised 529 women to either...

Sacituzumab govitecan should become the new standard of care in women with previously treated metastatic triple-negative breast cancer (mTNBC), according...


Cancel
Cancel